Table 1.
In vitro inhibitory activities of DFP against seventeen recombinant human KDMs.
| KDMs | IC50 (μM) |
|---|---|
| KDM1A (LSD1) | NIa |
| KDM2A (FBXL10) | 6.8 |
| KDM2B (FBXL11) | 8.1 |
| KDM3A (JMJD1A) | NIb |
| KDM3B (JMJD1B) | NIb |
| KDM4A (JMJD2A) | NIa |
| KDM4B (JMJD2B) | NIb |
| KDM4C (JMJD2C) | NIb |
| KDM4D (JMJD2D) | NIb |
| KDM4E (JMJD2E) | NIb |
| KDM5A (Jarid1A) | NIb |
| KDM5B (Jarid1B) | NIb |
| KDM5C (Jarid1C) | 5.6 |
| KDM6A (UTX) | 4.2 |
| KDM6B (JMJD3) | NIb |
| KDM7A (JHDM1D) | 16.6 |
| KDM7B (PHF8) | 15.6 |
aNo inhibition at maximum tested concentration of 25 μM.
bLess than 50% inhibition at maximum tested concentration of 25 μM.